Eyenovia Announces First Patients Enrolled in Phase 3 Study of MicroLine for Presbyopia

Eyenovia Announces First Patients Enrolled in Phase 3 Study of MicroLine for Presbyopia Eyenovia Announces First Patients Enrolled in Phase 3 Study of MicroLine for Presbyopia Topline Results Expected First Half of 2021 December 16, 2020…

Eyenovia Submits New Drug Application to FDA for Pharmacologic Mydriasis

Eyenovia Submits New Drug Application to FDA for Pharmacologic Mydriasis with MydCombi Targeting 80 Million Patient Encounters in the U.S. Annually December 29, 2020 07:00 AM Eastern Standard Time NEW YORK--(BUSINESS WIRE)--Eyenovia,…

Eyenovia To Report Third Quarter 2020 Results

NEW YORK, Nov. 05, 2020 (GLOBE NEWSWIRE) -- Eyenovia, Inc., (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose array print (MAP™) therapeutics, today announced that the Company will…